• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma

by MM360 Staff | Jan 7, 2026 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Scientists find new way to kill treatment-resistant myeloma cells

by Marisa Wexler, MS | Jan 6, 2026 | Myeloma News

Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body — may help eliminate myeloma cells that are resistant to conventional treatments, according to a new study led by U.S....

Phase 3 blood cancer vaccine trial moves toward final analysis

by Marisa Wexler, MS | Jan 5, 2026 | Myeloma News

A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer, is nearing its end, according to an update from the therapy’s developer, Sellas Life Sciences. The Phase 3 trial,...

Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review

by MM360 Staff | Jan 4, 2026 | Publications

Br J Haematol. 2026 Jan 2. doi: 10.1111/bjh.70323. Online ahead of print. ABSTRACT High-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM). A substantial...

MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma

by MM360 Staff | Jan 3, 2026 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
  • CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT